Seite - (000401) - in Biomedical Chemistry: Current Trends and Developments

microparticles. Vaccine, 30(35), 5206-5214. Gautier, J., Allard-Vannier, E., Munnier, E., et al. (2013). Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. Journal of Controlled Release, 169(1-2), 48-61. Gedeon, P. C., Riccione, K. A., Fecci, P. E., et al. (2014). Antibody-based immunotherapy for malignant glioma. Seminars in Oncology, 41(4), 496-510. Gjetting, T., Jolck, R. I., Andresen, T. L. (2014). Effective nanoparticle-based gene delivery by a protease triggered charge switch. Advanced Healthcare Materials, 3(7), 1107-1118. Godin, B., Tasciotti, E., Liu, X., et al. (2011). Multistage nanovectors: From concept to novel imaging contrast agents and therapeutics. Accounts of Chemical Research, 44(10), 979-989. Gomez, S., Gamazo, C., San Roman, B., et al. (2006). Development of a novel vaccine delivery system based on gantrez nanoparticles. Journal of Nanoscience and Nanotechnology, 6(9- 10), 3283-3289. Grinberg, S., Linder, C., Heldman, E. (2014). Progress in lipid-based nanoparticles for cancer therapy. Critical Reviews in Oncogenesis, 19(3-4), 247-260. Hamdy, S., Haddadi, A., Hung, R. W., et al. (2011). Targeting dendritic cells with nano-particulate plga cancer vaccine formulations. Advanced Drug Delivery Reviews, 63(10-11), 943-955. Hanke, N., Alizadeh, D., Katsanis, E., et al. (2013). Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Critical Reviews in Immunology, 33(1), 1-21. He, C., Hu, Y., Yin, L., et al. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31(13), 3657-3666. Heikenwalder, M., Polymenidou, M., Junt, T., et al. (2004). Lymphoid follicle destruction and immunosuppression after repeated cpg oligodeoxynucleotide administration. Nature Medicine, 10(2), 187-192. Helmlinger, G., Sckell, A., Dellian, M., et al. (2002). Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clinical Cancer Research, 8(4), 1284- 1291. Herranz-Blanco, B., Liu, D., Mäkilä, E., et al. (2015). On-chip self-assembly of a smart hybrid nanocomposite for antitumoral applications, Advanced Functional Materials, 25(10), 1488– 1497. Hillaireau, H., Couvreur, P. (2009). Nanocarriers’ entry into the cell: Relevance to drug delivery. Cellular and Molecular Life Sciences, 66(17), 2873-2896. Holohan, C., Van Schaeybroeck, S., Longley, D. B., et al. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714-726. Homma, S., Komita, H., Sagawa, Y., et al. (2005). Antitumour activity mediated by cd4+ cytotoxic t lymphocytes against mhc class ii-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology, 115(4), 451-461. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., et al. (2005). Sequence-specific knockdown of ews-fli1 by targeted, nonviral delivery of small interfering rna inhibits tumor growth in a murine model of metastatic ewing’s sarcoma. Cancer Research, 65(19), 8984-8992. Hu, C. M., Aryal, S., Zhang, L. (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic delivery, 1(2), 323-334. Hua, F., Swihart, M. T., Ruckenstein, E. (2005). Efficient surface grafting of luminescent silicon